Evidence map›Paper›PMID 34697764›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2021

Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes.

Mary Dena, Ann-Marie Svensson, Katarina Eeg Olofsson, Laura Young, Anders Carlson, Kellee Miller, Julia Grimsmann, Reinhard Welp, Julia K Mader, David M Maahs and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD.Journal of the American Society of Nephrology : JASN · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 4 countries.

Mary DenaDepartment of Medicine, NU Hospital Group, Uddevalla, Trollhättan, Sweden.
Ann-Marie SvenssonDepartment of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Katarina Eeg OlofssonDepartment of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Laura YoungDiabetes and Endocrinology Clinic at Meadowmont, UNC Hospitals, Chapel Hill, NC, USA.
Anders CarlsonInternational Diabetes Center, Minneapolis, MN, USA.
Kellee MillerJaeb Center for Health Research, Tampa, FL, USA.
Julia GrimsmannInstitute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany.
Reinhard WelpUniversity Duisburg-Essen, Bochum, Germany.
Julia K MaderDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
David M MaahsPediatric Endocrinology, Stanford University, Stanford, CA, USA.
Reinhard W HollInstitute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany.
Marcus LindDepartment of Medicine, NU Hospital Group, Uddevalla, Trollhättan, Sweden. marcus.lind@gu.se.ORCID http://orcid.org/0000-0002-3796-9283
NU Hospital Group · SEUniversität Ulm · DEUniversity of Gothenburg · SEJaeb Center for Health Research · USMedical University of Graz · ATStanford University · USUniversity of Duisburg-Essen · DEUniversity of North Carolina Health Care · US

Funding

German center for Diabetes 82DZD14A02
6 · The paper itself

Abstract

introductionRenal complications are both a marker of previous suboptimal glycaemic control and a major risk factor for cardiovascular disease in persons with type 1 diabetes (T1D). The aim of the study was to evaluate the prevalence of renal complications in persons with T1D in four geographical regions.

methodsNationwide registry data from Austria/Germany, Sweden and the US were used to estimate the prevalence of renal complications from January 2016 until September 2018. Chronic kidney disease (CKD) and albuminuria in the study population and each registry were analysed by diabetes duration. Risk factors for renal complications were described by registry.

resultsIn the total cohort of 78.926 adults with T1D, mean age was 44.4 ± 18.43 years and mean diabetes duration was 21.6 ± 22 years. Mean estimated glomerular filtration rate (eGFR) was 94.0 ± 31.45 ml/min, 13.0% had microalbuminuria and 3.9% had macroalbuminuria. Mean age, diabetes duration, use of insulin pumps and continuous glucose monitoring, as well as presence of albuminuria, varied between registries. Albuminuria was present in approximately 10% of persons with diabetes duration < 20 years and impaired renal function (eGFR < 60 ml/min) was present in 17%. In persons with diabetes duration > 40 years, approximately one-third had albuminuria and 25% had impaired renal function.

conclusionsThis analysis used three nationwide registries of persons with T1D. Despite recent use of more effective diabetes therapies, a substantial proportion of persons with T1D have renal complications at < 20 years after diagnosis. Efficient glucose-lowering and renal-protective strategies are needed in persons with T1D.

Indexed as

Chronic kidney diseaseMacroalbuminuriaMicroalbuminuriaNephropathyRenal complicationsType 1 diabetes

Identifiers

PMID34697764
PMCPMC8586278
OpenAlexW3210941464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.